Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

…, I Tirosh, L Imundo, R Jerath, DJ Kingsbury… - The Lancet, 2021 - thelancet.com
Background Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and
safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic …

[HTML][HTML] HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum

NS Dangoria, ML DeLay, DJ Kingsbury, JP Mear… - Journal of Biological …, 2002 - ASBMB
The class I protein HLA-B27 confers susceptibility to inflammatory arthritis in humans and
when overexpressed in rodents for reasons that remain unclear. We demonstrated previously …

Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood

…, AS Zeft, DJ Lovell, DJ Kingsbury… - … : Official Journal of …, 2009 - Wiley Online Library
Objective To compare the criteria for Wegener's granulomatosis (WG) of the American
College of Rheumatology (ACR) with those of the European League Against Rheumatism/…

[HTML][HTML] Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases

…, E Kessler, H Kim, DJ Kingsbury… - The Journal of …, 2020 - Am Soc Clin Investig
BACKGROUND Undifferentiated systemic autoinflammatory diseases (USAIDs) present
diagnostic and therapeutic challenges. Chronic interferon (IFN) signaling and cytokine …

Emergent high fatality lung disease in systemic juvenile arthritis

…, R Jerath, K Khawaja, DJ Kingsbury… - Annals of the …, 2019 - ard.bmj.com
Objective To investigate the characteristics and risk factors of a novel parenchymal lung
disease (LD), increasingly detected in systemic juvenile idiopathic arthritis (sJIA). Methods In a …

Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener's): an …

…, K Ede, M Shishov, DJ Kingsbury… - Arthritis & …, 2016 - Wiley Online Library
Objective To uniquely classify children with microscopic polyangiitis (MPA), to describe their
demographic characteristics, presenting clinical features, and initial treatments in …

Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial

…, N Rubio-Pérez, V Keltsev, DJ Kingsbury… - Annals of the …, 2018 - ard.bmj.com
Objective This report aims to determine the safety, pharmacokinetics (PK) and efficacy of
subcutaneous golimumab in active polyarticular-course juvenile idiopathic arthritis (polyJIA). …

[HTML][HTML] Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter …

…, Z Zuber, N Tzaribachev, DJ Kingsbury… - Pediatric …, 2017 - Springer
Background Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease
and a leading cause of childhood disability. The objective of this study was to characterize …

Association of Anti–3‐Hydroxy‐3‐Methylglutaryl‐Coenzyme A Reductase Autoantibodies With DRB1* 07: 01 and Severe Myositis in Juvenile Myositis Patients

…, IM Katona, H Kim, S Kim, DJ Kingsbury… - Arthritis care & …, 2017 - Wiley Online Library
Objective Autoantibodies recognizing 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR)
are associated with statin exposure, the HLA allele DRB1*11:01, and necrotizing …

[HTML][HTML] Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years

DJ Kingsbury, B Bader-Meunier, G Patel, V Arora… - Clinical …, 2014 - Springer
The objective of this study was to assess the safety of adalimumab in patients aged 2 to <4
years old or ≥4 years old weighing <15 kg with moderately to severely active polyarticular …